Michelson Diagnostics Secures CPT codes for Optical Coherence Tomography Imaging of Skin
Michelson Diagnostics announces that the American Medical Association (AMA) CPT Editorial Panel recently approved two new Category III CPT codes for Optical Coherence Tomography (OCT) imaging of skin. Code 0470T is for OCT microstructural and morphological imaging of skin, image acquisition, interpretation and report for a first lesion; code 0471T is the same for each additional lesion. The new Category III codes, which are for emerging technologies, services, and procedures, are effective July 1, 2017. Michelson Diagnostics pursued approval of this code at the AMA CPT Panel meeting in October 2017, receiving support from the American Academy of Dermatology.
“Obtaining the Category III CPT code for OCT of the skin is an important step towards our goal of obtaining reimbursement and coverage, and we welcome the new codes that can be used by clinicians to record their clinical use of VivoSight OCT in their practice” stated Jon Holmes, CEO of Michelson Diagnostics Inc.
A patient being imaged with the VivoSight Dx OCT Scanner
About Michelson Diagnostics’ VivoSight OCT scanner
Michelson Diagnostics’ innovative VivoSight Dx OCT scanner has FDA 510(k) clearance for use by trained clinicians for scanning skin lesions as an aid to assessing the patient’s condition. Using novel patented laser optics, it provides high-resolution subsurface images of skin tissue that reveal valuable information useful to the dermatologist. Potential clinical applications of OCT include use as an aid to diagnosis of non-melanoma skin cancer, monitoring non-invasive, non-scarring treatments, and mapping subsurface tumour borders prior to treatment. VivoSight OCT scanners are located at leading US hospital dermatology departments including at Icahn School of Medicine at Mount Sinai, New York, and Miami University School of Medicine, Florida.
About Michelson Diagnostics (www.vivosight.com)
Michelson Diagnostics is headquartered in Maidstone, UK, and has subsidiaries based near Nuremburg in Germany and in Stamford, Connecticut, USA. Founded in 2006 by Jon Holmes and colleagues, Michelson Diagnostics designs highly innovative instruments using multi-beam optical coherence tomography technology. It has been supported through funding from a syndicate of Venture Capital, corporate and private investors including Octopus, Catapult Ventures and Angel Investors. In the USA, Michelson Diagnostics is represented by Mondray Technologies Inc.
For clinical use in the US FDA 510(k) K093520 applies:
VivoSight is a Multi-Beam Optical Coherence Tomography (OCT) system indicated for use in the twodimensional, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions. US Federal law restricts this device to sale by or on the order of a physician.